Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AK114 in Advanced Solid Tumors
NCT05200273Phase 1Unknown
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK114 in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Incidence of adverse events (AEs) and Number of participants with a Dose Limiting Toxicity (DLTs) at 28 days. Status: unknown.
02
Drugs
AK114
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05200273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200273.